HCM
CAPR icon

Highbridge Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Highbridge Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,789,699
Closed -$9.54M – 363
2023
Q3 		$9.54M Buy
+2,789,699
New +$15.7M 0.4% 62

Other funds holding CAPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's CAPR Position: Q4 2023 in Review

Highbridge Capital Management sold out of Capricor Therapeutics (CAPR) in Q4 2023, closing a stake of 2,789,699 shares — an estimated $9.54M sold.

Highbridge Capital Management first reported a position in CAPR in Q3 2023 and held it in 1 quarter. The position peaked at $9.54M in Q3 2023. 37 funds tracked by Wall St. Rank hold CAPR as of Q4 2023.

  • Highbridge Capital Management reported no remaining Capricor Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Highbridge Capital Management sold 2,789,699 Capricor Therapeutics shares in Q4 2023, an estimated $9.54M.
  • Highbridge Capital Management first reported a position in Capricor Therapeutics in Q3 2023 and held it in 1 quarter.
  • Highbridge Capital Management's Capricor Therapeutics position peaked at $9.54M in Q3 2023.
  • 37 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2023.

Based on Highbridge Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.